2 Matching Annotations
  1. Last 7 days
    1. 4 U (2A/1) c.3389G > A p.Cys1130Tyr 26 D3-TIL-3 htz Missense na 14 14 23

      Case: IP #4 in type U VWD sub-cohort

      DiseaseAssertion: unclassified (2A/1) VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs:

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 14; VWF:Ac [IU/dL] = 14; FVIII:C [IU/dL] = 23

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.3389G>A p.Cys1130Tyr

      HGVS:

      ClinVarID: 1684001

      CAID:

      gnomAD: absent

    2. 5 U (2A/1) c.3389G > Ac.3539–10T > G Np.Cys1130Tyr-2626D3-TIL-3D3-TIL-3htzhtzMissenseSplice Sitena 17 16 20

      Case: IP #5 in type U VWD sub-cohort (also in row 3 splice variants table 6)

      DiseaseAssertion: unclassified (2A/1) VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs:

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 17; VWF:Ac [IU/dL] = 16; FVIII:C [IU/dL] = 20

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.3389G>A

      HGVS:

      ClinVarID: 1684001

      CAID:

      gnomAD: absent

      MultipleGeneVariants:

      Gene: VWF

      Variant: c.3539–10T>G

      ClinVarID: not found

      **gnomAD: absent